43 related articles for article (PubMed ID: 16086408)
21. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
22. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
23. Wip1 over-expression correlated with TP53/p14(ARF) pathway disruption in human astrocytomas.
Wang P; Rao J; Yang H; Zhao H; Yang L
J Surg Oncol; 2011 Nov; 104(6):679-84. PubMed ID: 21695702
[TBL] [Abstract][Full Text] [Related]
24. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
25. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
Agrawal A; Yang J; Murphy RF; Agrawal DK
Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
[TBL] [Abstract][Full Text] [Related]
27. Polymorphic variants in the p53 pathway.
Murphy ME
Cell Death Differ; 2006 Jun; 13(6):916-20. PubMed ID: 16557270
[No Abstract] [Full Text] [Related]
28. Rare occurrence of inactivating p53 gene mutations in primary non-astrocytic tumors of the central nervous system: reappraisal by yeast functional assay.
Nozaki M; Tada M; Matsumoto R; Sawamura Y; Abe H; Iggo RD
Acta Neuropathol; 1998 Mar; 95(3):291-6. PubMed ID: 9542595
[TBL] [Abstract][Full Text] [Related]
29. Ependymomas in children.
Kun LE; Kovnar EH; Sanford RA
Pediatr Neurosci; 1988; 14(2):57-63. PubMed ID: 3075039
[TBL] [Abstract][Full Text] [Related]
30. Tumour suppression by p53: a role for the DNA damage response?
Meek DW
Nat Rev Cancer; 2009 Oct; 9(10):714-23. PubMed ID: 19730431
[TBL] [Abstract][Full Text] [Related]
31. The biology of ependymomas and emerging novel therapies.
Saleh AH; Samuel N; Juraschka K; Saleh MH; Taylor MD; Fehlings MG
Nat Rev Cancer; 2022 Apr; 22(4):208-222. PubMed ID: 35031778
[TBL] [Abstract][Full Text] [Related]
32. Molecular Stratification of Childhood Ependymomas as a Basis for Personalized Diagnostics and Treatment.
Zaytseva M; Papusha L; Novichkova G; Druy A
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638438
[TBL] [Abstract][Full Text] [Related]
33. p53 Pathway dysfunction in primary childhood ependymomas.
Gaspar N; Grill J; Geoerger B; Lellouch-Tubiana A; Michalowski MB; Vassal G
Pediatr Blood Cancer; 2006 May; 46(5):604-13. PubMed ID: 16086408
[TBL] [Abstract][Full Text] [Related]
34. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
